ArticleCureus2025
Lactulose Versus Rifaximin Monotherapy for Hepatic Encephalopathy Prevention: A Prospective Comparative Study in Patients With Cirrhosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic encephalopathy (HE) is a serious complication of liver cirrhosis, often leading to frequent hospitalizations and reduced quality of life.
objectiveTo prospectively compare the efficacy, safety, and tolerability of lactulose versus rifaximin monotherapy in preventing recurrent HE among patients with cirrhosis across multiple tertiary centers. METHODOLOGY: This prospective, multi-center comparative observational study was conducted between November 2023 and October 2024 across three sites: Capital Hospital (Islamabad, Pakistan), AlBashir Hospital (Amman, Jordan), and Abbas Institute of Medical Sciences (Muzaffarabad, Azad Jammu and Kashmir). A total of 236 patients with cirrhosis with a prior episode of overt HE were randomly assigned to receive either rifaximin 550 mg twice daily or lactulose 30 mL three times daily for six months, followed by an additional six months of follow-up. Data were collected on treatment adherence, adverse effects, HE recurrence, and hospitalizations. Statistical analysis was performed using SPSS v26 (IBM Corp., Armonk, NY), with significance set at
resultsTreatment adherence ≥80% was achieved in 102 (86.4%) patients in the rifaximin group versus 85 (72.0%) in the lactulose group (
conclusionsRifaximin monotherapy demonstrated superior efficacy, safety, and tolerability compared to lactulose for preventing HE recurrence among patients with cirrhosis in a multi-center setting. These findings support rifaximin as a more effective long-term therapeutic option for secondary prophylaxis of HE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.